Beam Therapeutics
Base Editing

Beam Therapeutics is developing precision genetic medicines for serious diseases. Co-founded by scientific pioneers known for advancing CRISPR gene editing, Beam is the first company to pursue development of new therapies using CRISPR base editing technology. Beam aims to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes.


University
Harvard University
Massachusetts Institute of Technology
The Broad Institute
Sector
Life Science
Status
Active
Initial Investment Stage
Early
View Website